Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oncopeptides AB ( (SE:ONCO) ) has provided an announcement.
Oncopeptides AB has issued warrants to fulfill its obligations under a loan agreement with the European Investment Bank (EIB). This move involves a total of 2,788,416 warrants entitling the EIB to 3,383,326 ordinary shares, which will increase the company’s share capital by approximately SEK 375,925.13. The decision, authorized by the board of directors, allows Oncopeptides to meet its contractual obligations and potentially strengthens its financial position, impacting its operations and stakeholder interests.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate (PDC) platform, the company develops compounds that selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is marketed in Europe and has partnerships in South Korea, the Middle East, and Africa. Founded in 2000, Oncopeptides operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 5,729,925
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.43B
See more data about ONCO stock on TipRanks’ Stock Analysis page.